179 related articles for article (PubMed ID: 2029080)
21. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
[TBL] [Abstract][Full Text] [Related]
22. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
23. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
24. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
25. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
26. Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ
Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926
[No Abstract] [Full Text] [Related]
27. Anagrelide and the CALR mutation allele burden in essential thrombocythemia.
Atkinson E; Bakri M; Hayat A; Langabeer SE
Exp Oncol; 2018 Jun; 40(2):152-153. PubMed ID: 29949532
[No Abstract] [Full Text] [Related]
28. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.
Mills AK; Taylor KM; Wright SJ; Bunce I; Eliadis P; Brigden MC; Seeley G; Bashford J; Olsen T; Rentoul A; Kelly C
Aust N Z J Med; 1999 Feb; 29(1):29-35. PubMed ID: 10200810
[TBL] [Abstract][Full Text] [Related]
29. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
Petrides PE; Beykirch MK; Trapp OM
Eur J Haematol; 1998 Aug; 61(2):71-6. PubMed ID: 9714517
[TBL] [Abstract][Full Text] [Related]
30. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
31. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
Cacciola RR; Francesco ED; Giustolisi R; Cacciola E
Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995
[No Abstract] [Full Text] [Related]
32. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide.
Bellucci S; Legrand C; Boval B; Drouet L; Caen J
Br J Haematol; 1999 Mar; 104(4):886-92. PubMed ID: 10192455
[TBL] [Abstract][Full Text] [Related]
33. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
34. [Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
Kitanaka A; Shimoda K
Gan To Kagaku Ryoho; 2016 May; 43(5):535-8. PubMed ID: 27344681
[No Abstract] [Full Text] [Related]
35. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
[TBL] [Abstract][Full Text] [Related]
36. Long-term use of anagrelide in young patients with essential thrombocythemia.
Storen EC; Tefferi A
Blood; 2001 Feb; 97(4):863-6. PubMed ID: 11159509
[TBL] [Abstract][Full Text] [Related]
37. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
38. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists.
Reilly JT
Hematology; 2009 Feb; 14(1):1-10. PubMed ID: 19154658
[TBL] [Abstract][Full Text] [Related]
39. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Jurgens DJ; Moreno-Aspitia A; Tefferi A
Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
[TBL] [Abstract][Full Text] [Related]
40. Treatment of essential thrombocythemia with anagrelide.
Silverstein MN; Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
